Introduction: Several clinical guidelines indicate that brain metastasis screening (BMS) should be guided by disease stage in non-small cell lung cancer (NSCLC). We estimate that screening is performed more broadly in practice, and patients undergo brain imaging at considerable cost with questionable benefit. Our aim was to quantify the use and detection rate of BMS in a contemporary cohort staged with 18 F-fluorodeoxyglucose positron emission tomo-
Introduction
Non-small cell lung cancer (NSCLC) is the major malignant tumour resulting in brain metastases (BM). The overall incidence is around 40% during the course of the disease (including cases de novo), and 15-20% after an initial diagnosis of localised NSCLC. 1, 2 The lifetime occurrence increases with local staging, from 10% for stage I, to 30% in stage II and as much as 50% in locally advanced disease stage III. 3 Multiple series have demonstrated a low incidence of occult BM (without neurological signs or symptoms) at diagnosis. [4] [5] [6] In accordance with these findings, consensus guidelines on the initial staging of NSCLC tend to recommend against routine brain imaging in neurologically asymptomatic early stage patients (Stage I and II) Table 1 . When screening is performed MR tends to be the preferred modality. 5 Nevertheless, the detection of BM is highly significant for the individual patient. Brain metastases portend a poor prognosis and almost always lead to changes in treatment intent, modality and the sequencing and intensity of therapies. Furthermore, recent developments in the management of BM have shown potential positive outcomes in selected cases. Therefore, clinicians may be inclined to perform investigations in excess of the recommended staging.
Since the publication of many reports on the detection rate of occult BM at screening, the use of positron emission tomography-CT (PET-CT) in the staging of newly diagnosed NSCLC has become routine due to its superior performance compared to contrast-enhanced computed tomography (CE-CT) alone in detecting extra-cranial metastases. 7, 8 More accurate extra-cranial disease staging is likely to have an impact on the possible yield, and therefore the role, of brain metastasis screening (BMS) according to disease stage. In this study we sought to assess the current local BMS practices and to determine the rate of detection of occult BM in a modern PET-staged population according to extra-cranial disease stage.
Methods
We conducted a review of prospectively collected databases from lung cancer multidisciplinary meetings (MDM) between 2011 and 2015 at three major lung cancer referral centres in Brisbane (Princess Alexandra Hospital, The Prince Charles Hospital and Royal Brisbane and Women's Hospital). Consecutive patients with an initial diagnosis of NSCLC were identified. Only patients with PET-CT staging were included in the study. Patient demographics and tumour characteristics including disease stage were extracted. Seventh edition AJCC staging was used in this time period. 9 Brain metastasis screening was defined as dedicated brain imaging (CE-CT or MR) in the absence of neurological signs or symptoms. BMS was determined for each eligible patient by review of the MDM database and additional review of the patient's electronic medical record, which stores medical imaging reports from all public Queensland Health facilities. Descriptive statistics were reported as mean and standard deviation (SD) and categorical variables were described using frequencies and percentages. Substages were grouped together due to the low numbers of patients in T sub-stages and group sub-stages (T1a/ b = T1, T2a/b = T2; group stage Ia/b = I, IIa/b = II, IIIa/ b = III). The relationship between BM detection rates and BM screening rates with stage, gender and histology was assessed by Chi-squared tests or Fisher's exact tests when appropriate. The patient age was compared between groups using t-tests.
A logistic regression was performed to assess the relationship between screening and facility (A, B or C), and the interaction of age, gender and histology at each institution. Odds ratios (OR) with 95% confidence intervals (CI) were reported.
Results
We identified 1751 consecutive cases of NSCLC with PET-CT staging. At least 718 of these underwent BMS. Results are summarised in Table 2 . The majority underwent CE-CT imaging (n = 703), while the remainder had MR (n = 15).
Screening practices
The overall rate of BMS was 41%, and was not influenced by age (P = 0.16), gender (P = 0.14) or adenocarcinoma vs non-adenocarcinoma histology (P = 0.28). Screening rates did show a relationship to TNM staging. An overall difference was evident for T stage (P = 0.001). It seemed significantly higher in T3 and T4 stages than in T1 (P-values <0.001 and 0.04), and in T3 stage than in T2 stage (P = 0.01). Likewise, an overall difference for N stages was seen (P < 0.001), with a higher proportion of patients screened in N2 and N3 stages than in N0 (P < 0.001 and P = 0.04 respectively), and screening in stage N2 was higher than in N1 (P = 0.04). Consequently, there is also an overall relationship between BMS and group stage (P < 0.001), with screening in stage III being highest.
Screening rates were significantly higher in one of the three institutions (institution C), without significant differences between the other two (A and B). Patients were around three times more likely to be screened at this centre than in B (OR 2.91 CI 2.23-3.83, P = 0.000), and A (OR 3.24 CI 2.60-4.05; P = 0.000). Institution C also seemed to screen non-adenocarcinoma histology more frequently than adenocarcinoma histology (64% vs. 54%, P = 0.01), while histology showed no interaction with screening rates at A or B. However, this finding may be due to cases of adenocarcinoma being reported as NSCLC NOS. There was no apparent effect of age or gender on screening rates by institution. Screening with MRI was only performed in 15 patients. Although this is a very small number, there was no suggestion of this choice being influenced by particular factors.
Screening results
Occult brain metastases were detected in 18 patients (2.5%). Fourteen screening CE-CT scans led to an MRI scan to rule out metastases (false positives). The rate of occult brain metastasis increased with N-stage and overall stage. The detection rate was 0.5%, 1%, 1.6% and 7.3% for stage I, II, III and IV (excluding brain metastases) respectively (P < 0.001). There was no significant relationship for T-stage overall (P = 0.10).
Brain metastases were present in 0.5%, 3.4%, 2.9% and 3.8% of stage T1, T2, T3 and T4 screened patients respectively. Nodal status showed a significant overall relationship (P = 0.02). However, there were no significant differences between N1, N2 or N3. According to group stage, stage IV, based on the presence of extracranial metastasis, showed a significantly higher number of BM than all other stages.
Despite differences in screening rates, there was no significant difference in BM detection rates across centres.
Adenocarcinoma histology was present in 15 of the 18 cases of occult BMs, the remaining three cases were classified NSCLC NOS after comprehensive characterisation attempts. Anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) status were tested in 12 patients. Two were ALK re-arranged and one demonstrated an EGFR mutation.
Patient outcomes
In six of the patients with occult BM, the brain was the only site of metastasis. The other 12 patients had concurrent extra-cranial metastases. Seven patients underwent targeted treatment for their occult brain metastases (Table 3) , five of whom also had extra-cranial metastases. Eight patients received whole brain radiotherapy (WBRT) and two received no brain directed therapy in favour of best supportive care.
Ten patients received palliative dose thoracic radiotherapy and seven had no thoracic radiotherapy at all.
One patient did not have any records available after discussion in the MDM.
Cost analysis
In a simple calculation of the cost of screening performed in our cohort, AUD $187,442.8 were invested on screening scans and additional diagnostic MRI after false positive CE-CT screening. The cost per BM detected was AUD $10,413.5 (MBS schedule fee of AUD $250 per CE-CT head; AUD $403.20 MRI Brain).
Discussion
Our study indicates that BMS is carried out with relative frequency in patients across all disease stages with only marginal differences in screening according to PET-CT defined extra-cranial disease stage. The slight drop in screening rates in higher disease stages likely reflects a more frequent palliative approach to treatment in this group.
The rate of detection of asymptomatic brain metastases showed a logical relationship to extra-cranial disease stage, yet it is generally low across all groups. It was less than 1% for patients with stage T1a/b, N0 or group stage I, and reached only 7% in the presence of other distant metastases. The rate of detection in our study is consistent with other reports 4 despite the routine use of PET-CT in our patient population, which may have been expected to lower detection rates in early stage disease due to upstaging. 7 It is notable that 15 of the 18 patients with occult brain metastases had adenocarcinoma histology. No patient with proven squamous cell histology had occult BM detected. This finding is consistent with the predominance of non-squamous cell histology as cause of brain metastasis, as has been established in other studies. 3, 6, 10 One possible explanation for the high rates of BMS found in this study may be the clinicians' desire to prevent intensive loco-regional therapy from being administered to patients with otherwise incurable disease. Twelve of 18 patients in our study had evidence of extracranial metastases in addition to brain metastases and would have been recommended palliative treatment irrespective of the BMS result. In only six patients (<1% of the entire cohort), intensive loco-regional therapy would be expected to be avoided.
An alternative justification for the high rates of BMS screening may be to allow the aggressive management of oligometastatic disease.
Stereotactic radiosurgery for brain metastases has shown a survival advantage in patients with up to 3 BM in a secondary analysis of good prognosis patients.
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Neurosurgery for solitary brain metastasis has also demonstrated a survival benefit albeit in trials with smaller sample sizes. 12, 13 Under specific circumstances one may be favoured over the other, but in general there is equipoise between these two treatment modalities.
14 However, less than 50% of patients with brain metastases are found to be in a good prognosis category (GPA ≥ 2.5) (48% in the GPA cohort that included both symptomatic and asymptomatic subjects). 15 In our cohort, none of the patients with occult BM received a radical dose of thoracic radiotherapy (Table 3 ). This palliative approach is consistent with their anticipated poor prognosis. Nevertheless, seven patients underwent BM targeted treatment (craniotomy, stereotactic radiotherapy or Gamma Knife). Performance status (PS) was not recorded as per Karnofsky's score in our databases. Even assuming an excellent PS, most patients with BM (10 of 18) had low GPA (≤2.0), anticipating no survival advantage with directed local treatment of their brain metastases. 15 Thus, an overall survival benefit from the treatments delivered as a result of screening in our cohort is unlikely. It may have led to a delay in the onset of symptoms and improved QOL, which cannot be estimated with the data available.
The limitations of this study relate to its retrospective nature, particularly the potential failure to record events of interest, as it was prohibitive to search all private radiology providers in Queensland to rule out screening scans performed but not recorded in the MDM database or the electronic medical record of the 3 public hospitals. Nevertheless, we anticipate the impact of this on our findings to be limited, for several reasons. Firstly, all patients were seen in the public hospitals upon referral to the MDM. Staging scans performed by external referrers in the private sector would have been supplied for discussion and recorded in the MDM database. Most imaging obtained after the MDM would occur in the public hospital, and these results were found by cross-referencing the public hospital electronic medical record system. Furthermore, the observed differences in screening rates across N and group stages suggest validity of the documentation of the local practice, as it follows the generally accepted rationale to screen more advanced stages of disease. Secondly, it is possible that additional BMS scans may have been performed in the private sector and not captured by our study methods. However, these BMS scans are more likely to be negative, because a clinician encountering a positive result would normally return the patient to the MDM for a further discussion on management, where the result would be captured. Therefore, if this possible verification bias were to be controlled, the effect on the results could lower the rates of detection of BMS further, strengthening our conclusions.
A further limitation of the study would be that interobserver variability was not specifically controlled. However, imaging recorded in the MDM database is already 'double read', once by the reporting radiologist and again by the senior consultant radiologist at the MDM, in a process akin to centralised review.
Additionally, the very small number of events of BM found at screening, makes the analysis of possible relationships with influencing factors subject to sparse data bias.
Lastly, the low number of screening MR scans means that this analysis can only be applied to CE-CT screening and cannot be extrapolated to MR screening. MR is known to be superior to CE-CT in the detection of brain metastases, but studies on BMS have failed to prove a clinical benefit, 16 and its scarce use reflects issues of cost and access to this imaging modality.
Developing more specific screening recommendations
In the absence of high level evidence to guide BM screening practices in NSCLC, there appears to be several logical arguments to refine the patient selection criteria. It would seem appropriate to screen those with a higher risk of occult BMs who also have a potential survival benefit from an early diagnosis, or who would otherwise be offered aggressive loco-regional treatment that could be futile. A number of factors have been identified across several series that are of prognostic value at the time of diagnosing NSCLC brain metastasis. In the RTOG's GPA for NSCLC, age, performance status, presence of extracranial metastases and the number of brain lesions were significant independent prognostic factors. Only patients with scores of >2.0 achieved OS greater than 6 months.
An expected OS of more than 6 months has been widely adopted as selection criteria for aggressive management of BMs, with either neurosurgery or radiosurgery. Thus, applying the GPA, the patients that could potentially see a benefit if BMs are detected at screening would be:
• Those without EC metastases and KPS ≥70 • Those with EC metastases only if younger than 60 with KPS 90-100, or younger than 50 with PS ≥70.
Excluding performance status (i.e. assuming KPS = 100), applying these selection criteria to our cohort would drop the number of scans by 45%, and the resources invested would appear more than sufficient to allow for the routine use of MRI as the screening modality of choice. Thus, without an additional cost, the yield of screening could be enhanced for the individuals at highest risk. Patients who would not benefit from radical treatment to the primary and should avoid futile treatment, as well as patients in whom an aggressive treatment of their BM could offer significant survival gains, could be identified.
The more recent identification of molecular characteristics and utilisation of targeted therapies has clearly highlighted a group of patients with advanced NSCLC that can achieve longer survival. These cases are a minority, and these patients are characteristically young and generally healthy. Furthermore, in the case of ALK rearranged cancers, a particular neurotropism has been observed. 17 Therefore, it is possible that patients with either EGFR or ALK mutated tumours in reasonable performance status, regardless of their age, would also derive a potential benefit from early detection and management of BMs. Finally, histology type seems to be a predictive factor that is worth considering. However, other lung cancer cohorts have shown a non-significant association, and that histological grade and lymphovascular infiltration may be more powerful predictors. 3 The strength of these associations is undermined in our study by the low number of events recorded. Consider the use of MR imaging if available. Consider screening patients with lower PS if suitable for targeted therapy (EGFR or ALK mutant).
The above arguments should be considered in order to rationalise BMS in NSCLC. A summary of which is provided in Table 4 .
In conclusion, CE-CT brain metastasis screening is frequently performed in asymptomatic patients with a new diagnosis of non-small cell lung cancer. Our data highlights that local clinical practice favours unselective screening. The outcomes confirm the low yield of BM screening in a large cohort. A review of the selection criteria for screening NSCLC patients on presentation is warranted, which could improve the use of resources and patient outcomes.
